Pilot study of fractional microneedling radiofrequency for hidradenitis suppurativa assessed by clinical response and histology

2021 ◽  
Author(s):  
J.H. Yang ◽  
S.I. Cho ◽  
D.H. Kim ◽  
J.Y. Yoon ◽  
J. Moon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Clinical Response ◽  
Hidradenitis Suppurativa

Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab

Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Dimitra Stergianou ◽  
Vassiliki Tzanetakou ◽  
Maria Argyropoulou ◽  
Theodora Kanni ◽  
Pantelis G. Bagos ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Clinical Response ◽  
Odds Ratio ◽  
Hidradenitis Suppurativa ◽  
Positive Culture ◽  
Nasal Carriage ◽  
Loss Of Response ◽  
Response Score ◽  
Stimulation Of

<b><i>Background:</i></b> Several patients with hidradenitis suppurativa (HS) present flare-ups during treatment with adalimumab (ADA), the cause of which is not clear. ADA is the only FDA-approved biologic for the therapy of moderate-to-severe HS. A previous study of our group has shown that <i>Staphylococcus aureus</i> stimulation of whole blood affects the production of human β-defensin 2 and modulates HS severity. It is, therefore, hypothesized, that carriage of <i>S. aureus</i> may drive HS flare-ups. <b><i>Objective:</i></b> To explore the association between carriage of <i>S. aureus</i> and loss of response to ADA. <b><i>Patients and Methods:</i></b> Among patients with moderate-to-severe HS without carriage of <i>S. aureus</i> at start of treatment with ADA, we investigated for carriage of <i>S. aureus</i> from the nares when flare-ups occurred. Flare-ups were pre-defined as at least 25% increase of inflammatory lesions (sum of inflammatory nodules and abscesses) from baseline. Samplings were also done after completion of 12 weeks of ADA treatment from all patients who did not present flare-ups. Clinical response to ADA was assessed by the HS Clinical Response score (HiSCR). <b><i>Results:</i></b> Thirty-nine patients were studied; 24 with Hurley II stage HS and 15 with Hurley III stage HS. Twenty-nine patients achieved HiSCR after 12 weeks of treatment without any flare-ups; 10 patients had flare-ups and failed HiSCR. Three (10.3%) and 5 (50%) patients, respectively, had nasal carriage of <i>S. aureus</i> (odds ratio 8.67; 95% CI 1.54–48.49; <i>p</i> = 0.014). Among 32 patients reaching follow-up week 48, 20 patients achieved HiSCR and 12 had flare-ups leading to ADA failure; 2 (10%) and 5 (41.7%) patients, respectively, had positive culture for <i>S. aureus</i> (odds ratio 6.42; 95% CI 1.00–41.20; <i>p</i> = 0.05). <b><i>Conclusion:</i></b> Nasal carriage of <i>S. aureus</i> may be associated with loss of response to ADA. Findings need confirmation in larger series of patients.

scholarly journals Patterns of Clinical Response to PSA Elevation in American Indian/Alaska Native Men: A Multi-center Pilot Study

2013 ◽  
Vol 24 (4) ◽  
pp. 1676-1685
Author(s):  
Jon C. Tilburt ◽  
Kathryn Koller ◽  
James J. Tiesinga ◽  
Robin T. Wilson ◽  
Anne C. Trinh ◽  
...  
Keyword(s):  
Pilot Study ◽  
American Indian ◽  
Clinical Response ◽  
Alaska Native

scholarly journals IDDF2019-ABS-0293 A microbiome pilot study: the exploration of the gut-skin axis in hidradenitis suppurativa

2019 ◽  
Author(s):  
Suk Yee Lam ◽  
Djawad Radjabzadeh ◽  
Hester Eppinga ◽  
Hessel H van der Zee ◽  
Robert Kraaij ◽  
...  
Keyword(s):  
Pilot Study ◽  
Hidradenitis Suppurativa

Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study

2018 ◽  
Vol 48 (3) ◽  
pp. 333-339 ◽  
Author(s):  
C. R. Rowan ◽  
D. Keegan ◽  
K. Byrne ◽  
G. Cullen ◽  
H. E. Mulcahy ◽  
...  
Keyword(s):  
Pilot Study ◽  
Clinical Response ◽  
Drug Levels

Ustekinumab serum concentrations are associated with clinical outcomes in Crohn’s disease – a regional multi-center pilot study

2020 ◽  
Vol 58 (05) ◽  
pp. 439-444 ◽  
Author(s):  
Anne Kerstin Thomann ◽  
Lucas-Alexander Schulte ◽  
Anna-Maria Globig ◽  
Peter Hoffmann ◽  
Thomas Klag ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Pilot Study ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Roc Curve ◽  
Response To Therapy ◽  
Therapeutic Drug ◽  
Serum Concentrations ◽  
Serum Samples ◽  
Area Under Roc Curve

Abstract Background and aim The role of therapeutic drug monitoring (TDM) in ustekinumab (UST) therapy for Crohn’s disease (CD) has not been established, as only few studies have analyzed the relationship between UST serum concentrations and clinical outcome. In this pilot study, we retrospectively examined the potential of UST-concentrations (cUST) 8 weeks after induction (cUSTw8) to predict clinical response at week 16. Methods Serum samples and clinical data from patients (n = 72) with moderate to severely active CD who received intravenous induction with UST were retrospectively analyzed. cUST were quantitated using liquid chromatography-tandem mass spectrometry (LC-MSMS). A receiver-operating characteristic (ROC) curve and area under ROC curve (AUROC) was computed to analyze the predictive potential of cUSTw8 for clinical response at week 16 and to determine the minimal therapeutic UST trough concentration. Results Forty-four patients (61 %) achieved clinical response to UST therapy at week 16. cUSTw8 was moderately effective to predict clinical response with a minimal therapeutic cUSTw8 of 2.0 mg/l (AUC 0.72, p = 0.001). Conclusion Trough concentrations of UST 8 weeks after induction predict clinical response to therapy in week 16 with moderate sensitivity and specificity. TDM using LC-MSMS could prove beneficial in personalized UST therapy of patients with CD by identifying individuals with subtherapeutic concentrations who might benefit from dose escalation.

scholarly journals Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

2020 ◽  
Vol 21 (5) ◽  
pp. 741-748
Author(s):  
Øystein Grimstad ◽  
Bjørn Øivind Kvammen ◽  
Carl Swartling
Keyword(s):  
Botulinum Toxin ◽  
Pilot Study ◽  
Hidradenitis Suppurativa ◽  
Botulinum Toxin Type ◽  
Type B ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Botulinum Toxin Type B

scholarly journals 635 A novel method for evaluating physical signs of hidradenitis suppurativa: A pilot study

2019 ◽  
Vol 139 (5) ◽  
pp. S109
Author(s):  
N.I. Goldfarb ◽  
J.R. Ingram ◽  
G.B. Jemec ◽  
H.B. Naik ◽  
V. Piguet ◽  
...  
Keyword(s):  
Pilot Study ◽  
Hidradenitis Suppurativa ◽  
Novel Method

Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study

2005 ◽  
Vol 39 (5) ◽  
pp. 461-466 ◽  
Author(s):  
I COOK ◽  
A LEUCHTER ◽  
M MORGAN ◽  
W STUBBEMAN ◽  
B SIEGMAN ◽  
...  
Keyword(s):  
Pilot Study ◽  
Clinical Response

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

2014 ◽  
Vol 171 (6) ◽  
pp. 1434-1442 ◽  
Author(s):  
A.B. Kimball ◽  
G.B.E. Jemec ◽  
M. Yang ◽  
A. Kageleiry ◽  
J.E. Signorovitch ◽  
...  
Keyword(s):  
Clinical Response ◽  
Hidradenitis Suppurativa ◽  
Clinical Endpoint
Sign in / Sign up

Export Citation Format

Share Document